Skip to main content
Leo Luznik, MD, Hematology, Baltimore, MD, Johns Hopkins Hospital

LeoLuznikMD

Hematology • Baltimore, MD

Hematologic Oncology

Associate Professor of Oncology at Johns Hopkins University School of Medicine

Join to view full profile

Dr. Luznik is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Luznik's full profile

Already have an account?

  • Office

    401 N. Broadway
    Harry and Jeanette Weinberg Building
    Baltimore, MD 21231
    Phone+1 410-955-8964
    Fax+1 410-614-1005
  • Is this information wrong?

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1998 - 2000
  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1997 - 1998
  • University of Arizona College of Medicine-Tucson
    University of Arizona College of Medicine-TucsonResidency, Internal Medicine, 1994 - 1997
  • UC San Diego Medical Center - Hillcrest
    UC San Diego Medical Center - HillcrestPost-Doctoral Fellowship, Postdoctoral fellow (molecular biology), 1991 - 1994
  • University of Zagreb Faculty of Medicine
    University of Zagreb Faculty of MedicineClass of 1990

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1996 - Present
  • TX State Medical License
    TX State Medical License 2024 - 2024
  • MD State Medical License
    MD State Medical License 1997 - 2024

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • The European Society for Blood and Marrow Transplantation (EBMT) Consensus Recommendations for Donor Selection in Haploidentical Hematopoietic Cell Transplantation  
    Leo Luznik, Karen Ballen, Asad Bashey, Hillard M Lazarus, Bipin N Savani, Rizwan Romee, Ephraim J Fuchs, Nature
  • Small-Molecule BCL6 Inhibitor Effectively Treats Mice with Non-Sclerodermatous Chronic Graft-Versus-Host Disease  
    Joseph H Antin, Bruce Blazar, Leo Luznik, John Koreth, Ivan Maillard, Robert J Soiffer, James E Bradner, Jonathan S Serody, Jerome Ritz, Blood

Abstracts/Posters

  • Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML
    Leo Luznik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (_6...
    Leo Luznik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or M...
    Leo Luznik, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Spoiled for Choice: Donor Selection for Allogeneic Stem Cell Transplantation 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

  • Short Telomere Syndromes Cause a Primary T Cell Immunodeficiency
    Short Telomere Syndromes Cause a Primary T Cell ImmunodeficiencyOctober 22nd, 2020
  • Drug Regimen Enough to Control Immune Disease After Some Bone Marrow Transplants
    Drug Regimen Enough to Control Immune Disease After Some Bone Marrow TransplantsOctober 8th, 2014
  • How Common Chemo Drug Thwarts Graft Rejection in Bone Marrow Transplants
    How Common Chemo Drug Thwarts Graft Rejection in Bone Marrow TransplantsNovember 13th, 2013
  • Join now to see all

Hospital Affiliations

External Links

Dr. Leo Luznik, Dr. Leo Luznik, MD, Dr. L Luznik